Menu IR Home IR Home News Releases Events and Presentations Stock Information Stock Quote Interactive Stock Chart Key Ratios Analyst Coverage FAQs Financials and SEC Filings Annual Reports and Proxies Quarterly Financial Reports SEC Filings Corporate Governance Documents and Charters Management Board of Directors Committee Composition Contact the Board Contact Us News Releases Investor Alerts Year All Years 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Aug 20, 2020 Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function Aug 10, 2020 Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares Aug 4, 2020 Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock Aug 3, 2020 Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock Aug 2, 2020 Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis - Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis - Show 5102550100 per page«123456789…14»
